Hansa Biopharma AB (publ) (HNSBF PINK) stock market data APIs

$3.025 0(0%)
as of July 2, 2025
Try our APIs with free plan!

Hansa Biopharma AB (publ) Financial Data Overview

Price chart is built with Anychart

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis. In addition, the company evaluates imlifidase in three therapy areas, including autoimmune, gene therapy, and transplantation. It has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

Prev. Close 3.025
Open 3.025
High 3.025
Low 3.025
52 wk Range 2.83-3.65
Market Cap 248 M
Shares Outstanding 82 559 K
Revenue 182 M
EPS -0.0512
Beta 1.531

Why to choose EODHD?

Prices start at $19.99

24/7 Live support

Robust, powerful and reliable data

API Simplicity of a few lines of code


Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW

Get Hansa Biopharma AB (publ) data using free add-ons & libraries


Get Hansa Biopharma AB (publ) Fundamental Data

Hansa Biopharma AB (publ) Fundamental data includes:

  • Net Revenue: 182 M
  • EBITDA: -563 176 512
  • Earnings Per Share:
  • Income Statements
  • Balance Sheets
  • Cash flows

Plans with Fundamental data

Starting from

$ 59.99 /mo.
COMPARE PLANS

End-of-day & Earnings data

Get Hansa Biopharma AB (publ) Earnings data

Calendar & News package for

$ 19.99 /mo.

What’s included:

  • Latest Release: 2025-04-24
  • EPS/Forecast: NaN
GET THE PACKAGE

Get Hansa Biopharma AB (publ) End-of-day data

EOD Historical Data package for

$ 19.99 /mo.

What’s included:

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
GET THE PACKAGE

Hansa Biopharma AB (publ) News

Get Apple Inc fresh news feed via Financial News API

Calendar & News package for

$19.99/mo.

Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW
  • Flexibility: No long-term commitments, just a minimum of one month
  • Instant access: Get your API key and instructions within seconds of subscribing
  • Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.

What’s included:

  • API Calls per Day: 100 000/day
  • API Requests per Min.: 1000/minute
  • Type of Usage: Personal use

Data access:

Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.

GET THE PACKAGE
Chat